This chapter examines the competitive dynamics of the GLP-1 diet drug market, spotlighting Eli Lilly and Novo Nordisk's contrasting performances. It highlights Eli Lilly's recent success and strategic advantages, while addressing Novo's challenges amidst rising pressure. The discussion also touches on the societal impacts of these drugs, particularly in Bowling Green, Kentucky, and personal stories of individuals navigating the complexities of weight-loss treatments.
Featuring some of our favorite conversations of the week from our daily radio show “Bloomberg Businessweek.” Hosted by Carol Massar and Tim Stenovec.
Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 106.1 FM Boston, Bloomberg 960 AM San Francisco, WDCH 99.1 FM in Washington D.C. Metro, Sirius/XM channel 121, on the Bloomberg Business App, Radio.com, the iHeartRadio app and at Bloomberg.com/audio. You can also watch Bloomberg Businessweek on YouTube - just search for Bloomberg Global News.
Like us at Bloomberg Radio on Facebook and follow us on Twitter @carolmassar @timsteno and @BW
See omnystudio.com/listener for privacy information.